Immunology and Bi...
Follow
Find tag "Immunotherapy"
8.5K views | +3 today
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Scooped by Gilbert Faure au nom de l'ASSIM from Cancer Immunotherapy Review
Scoop.it!

Dermatology: Mobilizing the skin’s defense cells - A*STAR Research

Dermatology: Mobilizing the skin’s defense cells - A*STAR Research | Immunology and Biotherapies | Scoop.it
A*STAR researchers show that dermal dendritic cells migrate to the site of a sterile injury in a highly directed manner, independent of blood neutrophil migration

 

When skin is injured or exposed to a pathogen attack, the body’s immune system responds rapidly. But the exact skin-cell-based mechanisms behind these responses remain unclear. Now, A*STAR researchers have uncovered how skin-localized cells calleddermal dendritic cells (DDCs) respond to sterile skin injuries1. Their insights may help to develop new therapeutic interventions administered via the skin, and define the role of skin immune cells in autoimmune and metabolic diseases. 


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, June 18, 3:46 AM
HighlightsFeatures & InnovationsIn FocusAbout A*STAR Research|Register|News|SitemapDermatologyMobilizing the skin’s defense cells

Immune cells interact in surprising ways when responding to skin injuries

Published online 10 June 2015

Krishan Maggon 's curator insight, June 18, 3:48 AM


About A*STAR Research|DermatologyMobilizing the skin’s defense cells

Immune cells interact in surprising ways when responding to skin injuries

Published online 10 June 2015

Scooped by Gilbert Faure au nom de l'ASSIM from Immunopathology & Immunotherapy
Scoop.it!

"Adoptive T-Cell" Immunotherapy Shows Activity Against Advanced Ovarian Cancer in Phase I Study

"Adoptive T-Cell" Immunotherapy Shows Activity Against Advanced Ovarian Cancer in Phase I Study | Immunology and Biotherapies | Scoop.it

In a new study, researchers from the Perelman School of Medicine at the University of Pennsylvania School of Medicine show that a two-step personalized immunotherapy treatment — a dendritic cell vaccine using the patient’s own tumor followed by adoptive T cell therapy — triggers anti-tumor immune responses in advanced ovarian cancer patients.


Via Alfredo Corell
more...
Alfredo Corell's curator insight, February 10, 2013 5:55 AM

Most ovarian cancer patients are diagnosed with late stage disease that is unresponsive to existing therapies. In a new study, researchers from the Perelman School of Medicine at the University of Pennsylvania School of Medicine show that a two-step personalized immunotherapy treatment — a dendritic cell vaccine using the patients’ own tumor followed by adoptive T cell therapy — triggers anti-tumor immune responses in these type of patients. Four of the six patients treated in the phase I trial responded to the therapy, the investigators report this month in OncoImmunology.

 

Direct link to the journal: http://www.landesbioscience.com/journals/oncoimmunology/article/22664/?show_full_text=true&

Scooped by Gilbert Faure au nom de l'ASSIM from ORGANIC CHEMISTRY INTERNATIONAL
Scoop.it!

Dendritic cell-based nanovaccines for cancer immunotherapy

Dendritic cell-based nanovaccines for cancer immunotherapy | Immunology and Biotherapies | Scoop.it
Current Opinion in Immunology

Volume 25, Issue 3, June 2013, Pages 389–395

 

Dendritic cell-based nanovaccines for cancer immunotherapyLeonie E Paulis1,Subhra Mandal1,Martin Kreutz,Carl G FigdorDepartment of Tumor Immunology, Nijmegen Center for Molecular Life Sciences, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands

http://dx.doi.org/10.1016/j.coi.2013.03.001, How to Cite or Link Using DOI


Via Alfredo Corell, Anthony M Crasto DR.
more...
Alfredo Corell's curator insight, July 27, 2013 2:59 PM

Cancer immunotherapy critically relies on the efficient presentation of tumor antigens to T-cells to elicit a potent anti-tumor immune response aimed at life-long protection against cancer recurrence. Recent advances in the nanovaccine field have now resulted in formulations that trigger strong anti-tumor responses. Nanovaccines are assemblies that are able to present tumor antigens and appropriate immune-stimulatory signals either directly to T-cells or indirectly via antigen-presenting dendritic cells. This review focuses on important aspects of nanovaccine design for dendritic cells, including the synergistic and cytosolic delivery of immunogenic compounds, as well as their passive and active targeting to dendritic cells. In addition, nanoparticles for direct T-cell activation are discussed, addressing features necessary to effectively mimic dendritic cell/T-cell interactions.